Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Net Income (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Net Income data on record, last reported at -$24.6 million in Q3 2025.

  • For Q3 2025, Net Income fell 95.68% year-over-year to -$24.6 million; the TTM value through Sep 2025 reached -$81.8 million, down 139.21%, while the annual FY2024 figure was -$40.4 million, 80.6% down from the prior year.
  • Net Income reached -$24.6 million in Q3 2025 per CAPR's latest filing, up from -$25.9 million in the prior quarter.
  • Across five years, Net Income topped out at -$829093.0 in Q4 2023 and bottomed at -$25.9 million in Q2 2025.
  • Average Net Income over 5 years is -$9.9 million, with a median of -$7.4 million recorded in 2023.
  • Peak YoY movement for Net Income: skyrocketed 89.21% in 2023, then plummeted 745.66% in 2024.
  • A 5-year view of Net Income shows it stood at -$6.4 million in 2021, then dropped by 20.79% to -$7.7 million in 2022, then surged by 89.21% to -$829093.0 in 2023, then tumbled by 745.66% to -$7.0 million in 2024, then tumbled by 250.44% to -$24.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$24.6 million in Q3 2025, -$25.9 million in Q2 2025, and -$24.3 million in Q1 2025.